Oracle and Oxford Nanopore Team Up to Improve Healthcare and Speed Discovery of New Medical Breakthroughs

Oracle | September 16, 2021

Advances in DNA/RNA sequencing promise to revolutionize how medical communities identify, detect, and treat diseases and manage public health threats. To make this technology more accessible and increase its impact, Oracle has teamed up with Oxford Nanopore Technologies, the company behind a new generation of high-performance, rapid, scalable, and accessible sequencing technology.

Oracle and Oxford Nanopore have recently begun a collaboration to jointly explore several potential new solutions that would use genomic sequencing running on Oracle Cloud Infrastructure (OCI) to help speed medical breakthroughs and improve patient care.

Scientific researchers in more than 100 countries are already using nanopore sequencing to further their understanding of biology in a range of areas including human and cancer genetics as well as plant, animal, and environmental analyses. In addition, nanopore sequencing has been used for pathogen analysis, including the outbreak surveillance of tuberculosis, food-borne pathogens, Ebola, Zika, Lassa fever, dengue fever, influenza, and most recently COVID-19. 

As part of the collaboration, Oxford Nanopore will be using OCI in applied and clinical markets. Leveraging the high performance, security, and extensive reach of Oracle Cloud, Oracle and Oxford Nanopore will have the ability to extend population-scale genetic sequencing across the globe.

The organizations will also take on several ambitious projects spanning epidemiology, whole-genome sequencing, and healthcare and drug discovery. This includes integrating Oxford Nanopore's DNA/RNA sequencing capabilities and data into Oracle's broad portfolio of healthcare and life sciences applications to strengthen the links between genomics, medical treatment, and drug development.

Oxford Nanopore's innovative sequencing technology is unparalleled in the market for its ability to generate rich, accurate genomic data at any scale, from handheld devices to ultra-high output installations, By integrating genomic data into our existing applications and cloud infrastructure solutions, we can get these powerful tools into the hands of more people to solve critical health issues faster and improve patient outcomes to usher in a new era of genomic breakthrough.

- Mike Sicilia, executive vice president of Oracle Vertical Industries.

In parallel, Oracle has committed to investing £150 million in Oxford Nanopore, subject to customary conditions.

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud.


The world is on the cusp of an industrial revolution fueled by biotechnology and biomanufacturing. Emerging biological technologies are and will continue to transform the foundation of our physical world – everything from clothing, to plastics, to fuels, to concrete.


The world is on the cusp of an industrial revolution fueled by biotechnology and biomanufacturing. Emerging biological technologies are and will continue to transform the foundation of our physical world – everything from clothing, to plastics, to fuels, to concrete.

Related News


GenScript ProBio Enters into Strategic Partnership with RVAC Medicines

GenScript ProBio | February 24, 2023

GenScript ProBio, a renowned Contract Development and Manufacturing Organization (CDMO), has recently entered a strategic partnership agreement with RVAC Medicines Pte. Ltd., a biotech company specializing in the development and commercialization of mRNA vaccines and therapeutics. The collaboration is aimed at manufacturing GMP-grade plasmid DNA (pDNA) for the RVM-V001 mRNA COVID-19 vaccine candidate, as well as supporting future therapeutic pipelines. GenScript ProBio will offer GMP plasmid manufacturing service for RVAC Medicines' program, RVM-V001. By collaborating with GenScript ProBio, RVAC Medicines will be able to accelerate the clinical manufacturing of mRNA-based COVID-19 vaccines, as well as future mRNA-based vaccines designed to target other infectious diseases such as Clostriodioides difficile infection (CDI) and Respiratory syncytial virus (RSV). As RVAC proceeds with the development of its mRNA candidates, GenScript ProBio continues to offer high-quality GMP materials crucial to the objective, including plasmid DNA and the development of ancillary materials to support mRNA manufacturing processes. GenScript ProBio also provides consultative and expert guidance regarding regulatory and quality expectations of agencies worldwide. RVAC Medicines and GenScript ProBio will continue collaborating to support mRNA initiatives for both clinical and commercial stage development. Dr. Brian Min, CEO of GenScript ProBio said, "We are delighted to enter into this strategic partnership with RVAC Medicines. This collaboration will enable us to utilize our cutting-edge GMP plasmid manufacturing platform technology to support the development of mRNA-based COVID-19 vaccine and its therapeutic candidates." (Source – PR Newswire) About GenScript ProBio GenScript ProBio is a Contract Development and Manufacturing Organization (CDMO) that provides end-to-end drug discovery and commercialization services. The company's services are designed to accelerate drug development for its clients in various areas, including CGT, vaccines, biologics discovery, and antibody protein drugs. GenScript ProBio has a global presence, with subsidiaries in the Netherlands, the United States, South Korea, and China. Since October 2017, the company has helped clients in different regions, such as the United States, Europe, and Asia Pacific, to obtain over 40 IND approvals. Its goal is to drive innovation and speed up the biologics development process from target to market.

Read More

CELL AND GENE THERAPY, INDUSTRIAL IMPACT Announces the Launch of Compliance Mobile App for iOS | February 02, 2023

On February 1, 2023,, the biopharma industry's largest R&D marketplace, announced the release of a new iOS mobile app. The app provides a new, easy-to-use, on-the-go experience for purchase request approvals and compliance. In addition, iPhone users receive untethered notifications for accepting, delegating, and clarifying requests without needing to use their computers. The result is speedier approvals and fewer delays in scientific discovery. has spent the past fourteen years developing a digital marketplace that allows scientists to devote more time to science and less time to paperwork. The platform enables researchers to test more ideas in less time and at a lesser cost. It digitizes a company's complete research activities, automatically tracking purchases, contract management, payment processing, and generating business intelligence reports. Founder and CTO Chris Petersen commented, "One of the major barriers to drug discovery is the time it takes to ensure all compliance measures are met for a given research project, and understandably so." He added, "Our goal in building the Compliance Mobile App is to put compliance in the pocket of approvers, therefore minimizing the time it takes for researchers to move through the R&D process." (Source – Business Wire) Registered users of the platform can now get the Compliance Mobile App free from the Apple App Store About Founded in 2007, is the world's largest medical research marketplace. Its digital research platform combines a custom-built, cloud-native technology stack with a white-glove customer and scientific support, helping pharmaceutical scientists discover life-saving drugs in less time and at a lower cost. As a result, is accelerating and lowering the cost of medical research by connecting scientists and allowing them to exchange ideas and transact online effortlessly. The company now has a presence in enterprise marketplaces for 20 of the world's top 30 pharmaceutical firms, 80 biotechnology enterprises, and the National Institutes of Health in the United States (NIH).

Read More


Ligand’s Partner Travere Therapeutics Receives Accelerated Approval of FILSPARI™ by FDA

Ligand Pharmaceuticals | February 21, 2023

In a recent announcement by biopharmaceutical firm, Ligand Pharmaceuticals, the U.S. Food and Drug Administration (FDA) has given accelerated approval for FILSPARITM (sparsentan). This will be helpful in treating adults with primary IgAN condition who are at risk of rapid disease progression, typically defined as a urine protein-to-creatinine ratio (UPCR) of less than 1.5 g/g. FILSPARI, a once-daily oral medicine, is the first and only non-immunosuppressive therapy authorized for the treatment of IgAN. Two critical pathways are selectively targeted of IgAN (endothelin-1 and angiotensin II) to check disease progression. Up to 150,000 Americans may have the rare kidney illness IgAN, which is the main cause of kidney failure brought on by glomerular disease. Among these patients, it is predicted that 30,000 to 50,000 can be treated using the indication that has received accelerated approval. Travere has stated that it anticipates FILSPARI to be available from February 27, 2023, and it will offer a thorough patient support program all the way through the patient's therapeutic journey. Eric Dube, Ph.D., President and CEO of Travere Therapeutics, said, “The accelerated approval of FILSPARI is a significant milestone on our path to advancing a transformative treatment for the IgA nephropathy community.” He further added, “As a first-of-its-kind, non-immunosuppressive therapy, we believe FILSPARI has the potential to ultimately become the new standard of care for IgA nephropathy and offer hope to those living with this condition who until now have had few treatment options. We are grateful to the patients, caregivers, clinical trial investigators, healthcare providers, and advocates who have worked alongside us to develop this innovative first-in-class therapy.” (Source – Business Wire) About Ligand Pharmaceuticals Ligand Pharmaceuticals creates or acquires technologies that aid in the discovery and development of drugs by pharmaceutical firms. The company’s business model generates value for stockholders by offering a diverse portfolio of biotech and pharmaceutical product income streams, that are underpinned by an effective and low corporate cost structure.

Read More